GE HealthCare 3Q 2026: Revenue $5.51B, Net income $615M, EPS $1.36— 10-Q Summary

GE HealthCare reported Q3 2026 revenue of $5.51B, up 7.2% YoY, with net income at $615M and EPS at $1.36. Growth was driven by Pharmaceutical Diagnostics and Advanced Imaging Solutions, while U.S. and Canada revenue rose 13.3%.

Original reporting
Published Oct 28, 2026, 10:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 10:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GE HealthCare 3Q 2026: Revenue $5.51B, Net income $615M, EPS $1.36— 10-Q Summary — source image
Decision brief

The 30-second read

$GEHCBullishMed
01

Why it matters

The earnings beat suggests near‑term upside for the stock, while organic growth in PDx and AIS underscores longer‑term momentum.

02

Market read

First disclosure of Q3 2026 results for a large mid‑cap healthcare company; relevant for traders seeking earnings‑driven moves.

03

What to watch

Geopolitical headwinds in China and tariff costs could pressure margins despite the beat.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

The article summarizes the Q3 2026 10‑Q filing for GE HealthCare Technologies, highlighting key financial metrics and segment performance.

Company-level read

Ticker impact

$GEHCBullishHigh confidence
Context

GE HealthCare Technologies reported Q3 2026 revenue of $5.51B, net income $615M and EPS $1.36, all up YoY.

Expected impact

likely upward pressure as the market prices in the earnings beat

Evidence & confidence

The company posted double‑digit profit growth and revenue beat, which typically drives short‑term buying.

Market effects

Strong results may lift the broader medical‑technology sector.

U.S. and Canada revenue growth could boost North American healthcare indices.

Modest impact globally; European and Asian markets may see limited reaction.

Counterpoint

If guidance falls short of expectations, the rally could be short‑lived.

Key entities

  • GE HealthCare Technologies

    U.S.-listed medical‑technology firm (ticker GEHC).

Related articles

$GEHCMed

GE HealthCare Wins FDA Nod for AI Feeding Tube Detection Software

GE HealthCare received FDA clearance for Critical Care Suite 3.0, an AI software for feeding tube detection in X-ray imaging. The software supports both adult and pediatric patients, enhancing the company's AI-enabled imaging portfolio. GEHC shares rose 2% post-announcement, with a market cap of $37.51B. The software demonstrated high accuracy in testing, potentially increasing demand for GEHC's mobile imaging systems.

$GEHCMed

GE HealthCare Lands FDA Clearance for On-Device Feeding Tube AI

GE HealthCare received FDA clearance for Critical Care Suite 3.0, an AI software for mobile X-ray devices that detects feeding tubes in adults and children. The algorithm, running on-device, achieved 99.2% sensitivity and 91.6% localization accuracy. The company aims to enhance ICU and emergency department workflows, with plans for further AI releases in 2027.

$GEHCMedAI 9/10

GE HealthCare Technologies Inc.: GE HealthCare's Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial

GE HealthCare (GEHC) announced positive Phase 2 results for its MRI contrast agent mangaciclanol, meeting the primary endpoint and showing similar diagnostic preference to gadobutrol. The trial will advance to Phase 3, with mangaciclanol receiving FDA Fast Track designation. GEHC plans to present preliminary results at RSNA 2026.

$GEHCMed

GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial

GE HealthCare (GEHC) announced positive Phase 2 results for its MRI contrast agent mangaciclanol, advancing it to Phase 3 trials. The agent showed similar diagnostic performance to gadolinium-based agents and was well-tolerated. GEHC aims to address concerns with current contrast agents, such as tissue retention and supply chain issues. The FDA has granted mangaciclanol Fast Track designation.